Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377825643> ?p ?o ?g. }
- W4377825643 abstract "Abstract Background: Gemcitabine (GEM)-based chemotherapy is the standard treatment for pancreatic ductal adenocarcinoma (PDAC). However, the development of drug resistance limits its efficacy, and the specific mechanisms remain largely unknown. RUNX1, a key transcription factor in hematopoiesis, also involved in the malignant progression of PDAC, but was unclear in the chemoresistance of PDAC. Methods: We detected the expression of RUNX1 in the PDAC tissues by RT-PCR, immunohistochemistry (IHC) and western blot. The clinical significance of RUNX1 in PDAC was confirmed by single-or multivariate analysis and survival analysis. We established the stable expression cell lines with shRUNX1 and RUNX1 construct, and GEM-resistant cell lines was succeeded yet. The role of RUNX1 in GEM resistance was determined by CCK8 assay, plate colony formation assay and apoptosis analysis in vitro and in vivo. To explore the mechanism, we performed bioinformatic analysis using single-cell RNA sequencing(scRNA-seq) data from PDAC to screen for the endoplasm reticulum (ER) stress that was indispensable for RUNX1 in GEM resistance. We observed the cell morphology in ER stress by transmission electron microscopy and validated RUNX1 in gemcitabine resistance depended on the BiP/PERK/eIF2a pathway by in vitro and in vivo oncogenic experiments, using ER stress inhibitor(4-PBA) and PERK inhibitor (GSK2606414). The correlation between RUNX1 and BiP expression was assessed using TCGA RNA-seq dataset and validated by RT-PCR, immunostaining and western blot. The mechanism of RUNX1 regulating BiP was confirmed by ChIP-PCR and dual luciferase assay. Finally, the effect of RUNX1 inhibitor on PDAC was conducted in vivo mouse models, including subcutaneous xenograft and patient-derived xenograft (PDX) mouse models. Results: RUNX1 was aberrantly expressed in PDAC and was closely associated with responses to GEM-based chemotherapy. Silencing of RUNX1 could reverse GEM resistance in drug-resistant cell lines, and its inhibitor Ro5-3335 displayed a synergistic effect in inhibiting tumor growth in GEM-resistant xenograft and PDX mouse models, enhancing the anti-tumor activity of GEM. In detail, forced expression of RUNX1 in PDAC cells suppressed apoptosis induced by GEM exposure, which was reversed by the ER stress inhibitor 4-PBA and GSK2606414. RUNX1 modulating ER stress mediated gemcitabine resistance was supported by the analysis of our single cell RNA sequencing data. Consistently, silencing of RUNX1 strongly inhibited the GEM-induced activation of BiP and PERK/eIF2a signaling, one of the major pathways involved in ER stress. It was identified that RUNX1 directly binds to the BiP promoter, a key direct ER stress initiator, and stimulates BiP expression to enhance the capacity for cell adaptation, which in turn facilitates GEM resistance in PDAC cells. Conclusions: This study identified RUNX1 as a predictive biomarker for response to GEM-based chemotherapy. RUNX1 inhibition may represent an effective strategy for overcoming GEM resistance in PDAC cells." @default.
- W4377825643 created "2023-05-24" @default.
- W4377825643 creator A5001203824 @default.
- W4377825643 creator A5002724226 @default.
- W4377825643 creator A5004824893 @default.
- W4377825643 creator A5016043975 @default.
- W4377825643 creator A5030956493 @default.
- W4377825643 creator A5032050651 @default.
- W4377825643 creator A5034247665 @default.
- W4377825643 creator A5038011506 @default.
- W4377825643 creator A5046972210 @default.
- W4377825643 creator A5050510042 @default.
- W4377825643 creator A5065859286 @default.
- W4377825643 creator A5069820275 @default.
- W4377825643 creator A5072237935 @default.
- W4377825643 creator A5077930203 @default.
- W4377825643 date "2023-05-23" @default.
- W4377825643 modified "2023-09-26" @default.
- W4377825643 title "Combination of RUNX1 inhibitor and gemcitabine to mitigate chemo‐resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2a-axis-mediated endoplasmic reticulum stress" @default.
- W4377825643 cites W1736968472 @default.
- W4377825643 cites W1968486675 @default.
- W4377825643 cites W2008102732 @default.
- W4377825643 cites W2064054876 @default.
- W4377825643 cites W2074794487 @default.
- W4377825643 cites W2128327076 @default.
- W4377825643 cites W2131110612 @default.
- W4377825643 cites W2137522359 @default.
- W4377825643 cites W2147052402 @default.
- W4377825643 cites W2154816100 @default.
- W4377825643 cites W2161371146 @default.
- W4377825643 cites W2183650796 @default.
- W4377825643 cites W2192943385 @default.
- W4377825643 cites W2586926303 @default.
- W4377825643 cites W2605588696 @default.
- W4377825643 cites W2613045338 @default.
- W4377825643 cites W2747955726 @default.
- W4377825643 cites W2748536831 @default.
- W4377825643 cites W2789906546 @default.
- W4377825643 cites W2888330783 @default.
- W4377825643 cites W2904223696 @default.
- W4377825643 cites W2913002812 @default.
- W4377825643 cites W2971699541 @default.
- W4377825643 cites W2972602909 @default.
- W4377825643 cites W2983567059 @default.
- W4377825643 cites W3036374155 @default.
- W4377825643 cites W3099817120 @default.
- W4377825643 cites W3103606682 @default.
- W4377825643 cites W3110417472 @default.
- W4377825643 cites W3112907857 @default.
- W4377825643 cites W3157351142 @default.
- W4377825643 cites W4206841660 @default.
- W4377825643 cites W4220955106 @default.
- W4377825643 cites W4313530373 @default.
- W4377825643 doi "https://doi.org/10.21203/rs.3.rs-2944766/v1" @default.
- W4377825643 hasPublicationYear "2023" @default.
- W4377825643 type Work @default.
- W4377825643 citedByCount "0" @default.
- W4377825643 crossrefType "posted-content" @default.
- W4377825643 hasAuthorship W4377825643A5001203824 @default.
- W4377825643 hasAuthorship W4377825643A5002724226 @default.
- W4377825643 hasAuthorship W4377825643A5004824893 @default.
- W4377825643 hasAuthorship W4377825643A5016043975 @default.
- W4377825643 hasAuthorship W4377825643A5030956493 @default.
- W4377825643 hasAuthorship W4377825643A5032050651 @default.
- W4377825643 hasAuthorship W4377825643A5034247665 @default.
- W4377825643 hasAuthorship W4377825643A5038011506 @default.
- W4377825643 hasAuthorship W4377825643A5046972210 @default.
- W4377825643 hasAuthorship W4377825643A5050510042 @default.
- W4377825643 hasAuthorship W4377825643A5065859286 @default.
- W4377825643 hasAuthorship W4377825643A5069820275 @default.
- W4377825643 hasAuthorship W4377825643A5072237935 @default.
- W4377825643 hasAuthorship W4377825643A5077930203 @default.
- W4377825643 hasBestOaLocation W43778256431 @default.
- W4377825643 hasConcept C104317684 @default.
- W4377825643 hasConcept C121608353 @default.
- W4377825643 hasConcept C139447449 @default.
- W4377825643 hasConcept C158617107 @default.
- W4377825643 hasConcept C190283241 @default.
- W4377825643 hasConcept C2776415932 @default.
- W4377825643 hasConcept C2780258809 @default.
- W4377825643 hasConcept C502942594 @default.
- W4377825643 hasConcept C54355233 @default.
- W4377825643 hasConcept C55493867 @default.
- W4377825643 hasConcept C81885089 @default.
- W4377825643 hasConcept C86803240 @default.
- W4377825643 hasConcept C95444343 @default.
- W4377825643 hasConceptScore W4377825643C104317684 @default.
- W4377825643 hasConceptScore W4377825643C121608353 @default.
- W4377825643 hasConceptScore W4377825643C139447449 @default.
- W4377825643 hasConceptScore W4377825643C158617107 @default.
- W4377825643 hasConceptScore W4377825643C190283241 @default.
- W4377825643 hasConceptScore W4377825643C2776415932 @default.
- W4377825643 hasConceptScore W4377825643C2780258809 @default.
- W4377825643 hasConceptScore W4377825643C502942594 @default.
- W4377825643 hasConceptScore W4377825643C54355233 @default.
- W4377825643 hasConceptScore W4377825643C55493867 @default.
- W4377825643 hasConceptScore W4377825643C81885089 @default.
- W4377825643 hasConceptScore W4377825643C86803240 @default.
- W4377825643 hasConceptScore W4377825643C95444343 @default.
- W4377825643 hasLocation W43778256431 @default.